Advertisement
Journal Home
Search for

Volume 35, Issue 3, Pages 343-349 (March 2007)


View previous. 2 of 20 View next.

Adenoviral vectors for transient gene expression in human primitive hematopoietic cells: Applications and prospects

Marcus Järåsa, Ann C.M. Bruna, Stefan Karlssona, Xiaolong FanabCorresponding Author Informationemail address

Received 10 October 2006; received in revised form 10 October 2006; accepted 7 November 2006.

The proliferation and differentiation of primitive hematopoietic cells is tightly controlled by a number of signaling pathways. Transient blockage or enhancement of these signaling pathways may provide a new approach to manipulate the proliferation and differentiation of primitive hematopoietic cells. Adenoviral vectors have in recent years emerged as powerful tools for transient gene expression in human primitive hematopoietic cells. Important advantageous properties of adenoviral vectors include: feasible production of high-titer vector preparations, high efficiency in transducing both quiescent and actively dividing cells, high levels of transient gene expression, and a lack of mutagenic properties associated with integrating vectors. Progress in adenoviral fiber retargeting was recently demonstrated to enable high gene transfer efficiency into nondividing human CD34+ cells and nonobese diabetic/severe combined immunodeficient mouse bone marrow repopulating cells (SRCs), via the ubiquitously expressed CD46 as a cellular receptor. Importantly, fiber-retargeted adenoviral vectors can be engineered to report gene expression in single living CD34+ cells, thereby facilitating the isolation and characterization of SRCs and its downstream progenitors based on intrinsic signaling pathways. This review focuses on the current progress and the potential future applications of adenoviral gene transfer into human primitive hematopoietic cells and leukemic cells.

a Section of Molecular Medicine and Gene Therapy, Lund Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund, Sweden

b Section of Immunology, Lund University, Lund, Sweden

Corresponding Author InformationOffprint request to: Xiaolong Fan, M.D., Ph.D., Section of Molecular Medicine and Gene Therapy, BMC A12, 221 84 Lund, Sweden

PII: S0301-472X(06)00700-4

doi:10.1016/j.exphem.2006.11.004


View previous. 2 of 20 View next.